Skip to main content

Computational Drug Discovery of Medicinal Compounds for Cancer Management

129kviews
Editorial07 December 2023
Editorial: Computational drug discovery of medicinal compounds for cancer management

Management." This research topic attracted the interest of researchers, and a large number of manuscripts were submitted. Among these submissions, 15 Original Research articles have been published covering a wide range of CADD topics and elucidating advanced in silico methodologies applicable to the field of drug discovery.The following is a summary of the published articles: Dain Md Opo et al. used structure-based pharmacophore modeling and virtual screening to identify potentially natural lead compounds that can inhibit BRAF and thus can inhibit cancer. Promising candidate compounds targeting the upregulated BRAF gene have been identified using in silico drug design methodologies and computational tools. The study identified four potential compounds by utilizing these computational methods. The investigation suggests that these compounds may be useful against a range of cancers by specifically targeting the overexpressed BRAF gene (Dain Md Opo et al., 2022).

Threonine Kinase (TTK), a target in a variety of human cancers including breast, colorectal, and thyroid carcinomas. They used computational techniques like 3D-QSAR modeling and structure-based alignment. The study identified key factors influencing compound activity (electrostatic, steric, HBA, HBD, and hydrophobic fields). New compounds with predicted binding modes and structural stability were designed using molecular docking and molecular dynamics (MD) simulations, displaying promising TTK protein binding affinity as potential TTK inhibitor candidates (Ashraf et al., 2022). Li et al. investigated LSD1,a protein methylation oxidase linked to gene expression and tumor initiation. Compound 17i showed promise as an LSD1 inhibitor and anti-tumor agent, but solubility issues hampered clinical validation. A carrier-free 17i nano assembly made with DSPE-PEG2000 improved therapeutic efficacy. In CT-26 mice with colorectal tumors, these nano assemblies matched 17i's cytotoxicity in vitro but had better therapeutic efficacy, anti-tumor immune response, and lower systemic toxicity. A novel drug nanoassembly method may improve the effects of poorly soluble anti-tumor compounds (Li et al., 2022).He et al. computationally screened a library of 700 antiviral compounds against the 3CL protease (3CLP) of human noroviruses. The researchers discovered three compounds that had higher binding energy with 3CLP than the control (Dipeptidyl inhibitor 7). These hits' estimated physicochemical and ADME properties were in the favorable range. According to the findings, these compounds could be used as 3CLP inhibitors in the treatment of gastroenteritis (He et al., 2022).

Caulerpa spp. against the colorectal cancer enzymes glucose-6-phosphate dehydrogenase and 6-phosphoglutarate dehydrogenase. Caulerpin, monomethyl caulerpinate, and caulersin bind to these enzymes strongly. They proposed that the identified compounds be tested for their potential efficacy against enzymes in the pentose phosphate pathway (Mert-Ozupek et al., 2022).

C33A cervical cancer cells. The antiproliferative and apoptotic effects of CAR were mostly observed in C33A cervical cancer cells in vitro. ROS production in C33A mitochondria triggered a chain of events that resulted in mitochondrial apoptosis. CAR also influences extrinsic or death receptor pathway signaling. CAR inhibited hedgehog signaling, causing apoptosis and inhibiting cell proliferation in cervical carcinoma cells. These findings imply that CAR could be used to treat cervical cancer (Ahmad et al., 2022).

and Spreading Hedyotis Herb. They demonstrated how AR-SH reduces lung adenocarcinoma (LUAD) symptoms by targeting EGFR, MAPK1, and KRAS. Molecular docking and dynamics simulations showed that AR-SH's main active components bind to the right proteins, especially EGFR, suggesting it is more effective than Gefitinib. These findings show that AR-SH can improve LUAD treatment and prognosis (Guo et al., 2023).Almukadi et al. identified novel and efficacious therapeutics for PIM-1 kinase by employing structure-based and machine-learning approaches. Four potential molecules were discovered to modulate PIM-1. Additionally, the MD simulation study revealed that these compounds interacted with the PIM kinase stably (Almukadi et al., 2023).Alsukaibi et al. investigated the phytochemical and biological properties of two date fruit cultivars from Saudi Arabia's Ha'il region, Shishi M1 and Majdool M2. In vitro, both cultivars inhibited HCT-116 colon cancer cells. Procyanidin B2 and luteolin-7-O-rutinoside were identified as active constituents by computational analysis (Alsukaibi et al., 2023).

HRAS protein function. Fifty nonsynonymous single nucleotide polymorphisms (nsSNPs) were discovered, 23 of which were in the HRAS gene exon, implying that they are potentially harmful. Ten of the twenty-three tested substances were the most dangerous. This study lends credence to the notion that nsSNPs may increase HRAS expression and activate carcinogenic signaling pathways in cancer (Ali et al., 2023a).Ali et al. utilized phytocompounds targeting TP53 from Amomum subulatum seed extract, focusing on major alkaloids and saponins. The antioxidant activity was confirmed by DPPH analysis, particularly in methanol, BHT, and n-hexane extracts. Additionally, the computational analysis revealed that top phytocompounds had strong binding affinities to TP53, implying potential anti-cancer actions. This study presents novel cancer treatment drug discovery insights using Amomum subulatum seed compounds (Ali et al., 2023b).

cancer patients during the COVID-19 pandemic. Cancer patients, especially those suffering from depression, had higher levels of proinflammatory cytokines and oxidative stress markers than healthy people. Elevated levels of specific serum antibodies in cancer patients suggested increased oxidative stress. The findings highlight the importance of addressing mental health concerns in cancer patient care and disease management (Binsaleh et al., 2023). Rashid et al. investigated the potential of imidazole derivatives as MCF-7 inhibitors for the treatment of breast cancer. Using Flare's machine learning, they developed a 3D-QSAR and activity atlas model that classified compound datasets as active or inactive in comparison to a reference drug. Molecular docking analysis discovered active compound interactions with TTK, HER2, GR, NUDT5, MTHFS, and NQO2. The most promising cancer inhibitor was identified as compound C10, paving the way for new approaches to breast cancer treatment (Rashid et al., 2023). Hua et al. computationally screened 4, They observed that two potent compounds, BMS-754807 and GSK429286A, had high affinities for binding to GSK3β. These compounds also have promising drug-like properties.This study proposed that BMS-754807 and GSK429286A undergo experimental validation to assess their potential as anti-cancer agents (Hua et al., 2023). (Mukhtar et al., 2023).Finally, the authors and editors of this research topic hope that the collection of articles will highlight the advances made in the use of computational methodologies for facilitating the design of pharmaceutical compounds directed at various protein targets implicated in cancer management. Furthermore, it is expected that these articles will contribute to a deeper and more comprehensive understanding of the intricate biological processes that underpin cancer, potentially leading to novel therapeutic interventions for this disease. We hope that these articles will serve as a source of motivation, information, and guidance for researchers and scholars working in this field.

2,933 views

3 citations

The combination of multi-approach studies to explore the potential therapeutic mechanisms of imidazole derivatives as an MCF-7 inhibitor in therapeutic strategies
ORIGINAL RESEARCH
27 June 2023
The combination of multi-approach studies to explore the potential therapeutic mechanisms of imidazole derivatives as an MCF-7 inhibitor in therapeutic strategies
Maryam Rashid, 6 more and Rashid Ahmed Khan
Breast cancer covers a large area of research because of its prevalence and high frequency in all over the world. This study is based on drug discovery against breast cancer for a series of imidazole derivatives. A 3D-QSAR and activity atlas model was developed by exploring the dataset computationally, using machine learning process of Flare. The dataset of compounds was divided into active and inactive compounds according to their biological and structural similarity with the reference drug. The obtained PLS regression model has provided acceptable r 2 =0.81 and q 2 = 0.51.Protein-ligand interactions of active molecules were shown by molecular docking against 6 potential targets namely, TTK, HER2, GR, NUDT5, MTHFS and NQO2. Then toxicity risk parameters were evaluated for hit compounds. Finally, after all these screening processes, compound C10 was recognized as the best hit compound. This study identified new inhibitor C10 against cancer and provide an evidence-based knowledge to discover more analogues.

7,537 views

18 citations

ORIGINAL RESEARCH
7 June 2023
Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies
Rua M. Mukhtar, 15 more and Abdulrahim A. Alzain

6,372 views

13 citations

ORIGINAL RESEARCH
26 April 2023
Amomum subulatum: A treasure trove of anti-cancer compounds targeting TP53 protein using in vitro and in silico techniques
Sadaqat Ali, 8 more and Rohit Sharma
Amomum subulatum: A treasure trove of anti-cancer compounds targeting TP53 protein using in vitro and in silico techniques
Cancer is a major global health concern, and researchers are seeking innovative approaches to combat the disease. Clinical bioinformatics and high-throughput proteomics technologies have provided researchers with powerful tools to explore cancer biology. Medicinal plants are considered effective therapeutic agents, and computer-aided drug design (CAAD) is being used to identify novel drug candidates from plant extracts. The tumor suppressor protein TP53 is an attractive target for drug development, given its crucial role in cancer pathogenesis. In this study, we utilized a dried extract of Amomum subulatum seeds to identify phytocompounds that target TP53 in cancer. The extract was subjected to qualitative tests to determine its phytochemical composition. The team used diverse bioinformatics computational methods to evaluate the effect of Amomum subulatum and its natural components on TP53. These techniques included protein structural analysis, interactive comparison, alignment, and superposition of TP53 protein structures in 3D. We also conducted molecular docking and molecular dynamic (MD) simulation experiments to examine the binding interaction of the selected compounds with TP53. Based on virtual screening, the top three phytocompounds (tannins, saponins, and steroids) were selected based on their high binding energy and pharmacophore fit score. These compounds exhibited strong antioxidant activity and inhibited cancer cell inflammation in the TP53 pathway. MD simulations indicated that the ligand was bound to the protein with some significant conformational changes in the protein structure. This study provides novel insights into the development of innovative drugs for the treatment of cancer and inflammatory disorders. The use of medicinal plants in drug discovery is a promising area of research, and the findings of this study suggest that phytocompounds could serve as effective therapeutic agents for cancer and other diseases.

6,619 views

28 citations

ORIGINAL RESEARCH
21 April 2023
Predicting the effects of rare genetic variants on oncogenic signaling pathways: A computational analysis of HRAS protein function
Sadaqat Ali, 9 more and Mohammed Bourhia

6,407 views

20 citations

5,747 views

14 citations

ORIGINAL RESEARCH
10 March 2023
Combining machine learning and structure-based approaches to develop oncogene PIM kinase inhibitors
Haifa Almukadi, 5 more and Babajan Banaganapalli

4,910 views

9 citations

Combined 3D-QSAR, molecular docking and dynamics simulations studies to model and design TTK inhibitors
TTK (Tyrosine threonine kinase) is the key component of the spindle assembly checkpoint (SAC) that ensures correct attachment of chromosomes to the mitotic spindle and thereby their precise segregation into daughter cells by phosphorylating specific substrate proteins. The overexpression of TTK has been associated with various human malignancies, including breast, colorectal and thyroid carcinomas. TTK has been validated as a target for drug development, and several TTK inhibitors have been discovered. In this study, ligand and structure-based alignment as well as various partial charge models were used to perform 3D-QSAR modelling on 1H-Pyrrolo[3,2-c] pyridine core containing reported inhibitors of TTK protein using the comparative mo-lecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) approaches to design better active compounds. Different statistical methods i.e., correlation coefficient of non-cross vali-dation (r2), correlation coefficient of leave-one-out cross-validation (q2), Fisher’s test (F) and bootstrapping were used to validate the developed models. Out of several charge models and alignment-based approaches, Merck Molecular Force Field (MMFF94) charges using structure-based alignment yielded highly predictive CoMFA (q2 = 0.583, Predr2 = 0.751) and CoMSIA (q2 = 0.690, Predr2 = 0.767) models. The models exhibited that electrostatic, steric, HBA, HBD, and hydrophobic fields play a key role in structure activity relationship of these compounds. Using the contour maps information of the best predictive model, new compounds were designed and docked at the TTK active site to predict their plausible binding modes. The structural stability of the TTK complexes with new compounds was confirmed using MD simulations. The simulation studies re-vealed that all compounds formed stable complexes. Similarly, MM/GBSA method based free energy calcu-lations showed that these compounds bind with reasonably good affinity to the TTK protein. Overall molecular modelling results suggest that newly designed compounds can act as lead compounds for the optimization of TTK inhibitors.

11,290 views

41 citations

ORIGINAL RESEARCH
6 December 2022
In-silico molecular interactions among the secondary metabolites of Caulerpa spp. and colorectal cancer targets
Nazli Mert-Ozupek, 4 more and Hulya Ellidokuz

6,200 views

6 citations

Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process
ORIGINAL RESEARCH
4 October 2022
Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process
F. A. Dain Md Opo, 6 more and Jesus Simal-Gandara
The BRAF gene is responsible for transferring signals from outside of the cell to inside of the nucleus by converting a protein namely B-Raf through the RAS/MAPK pathway. This pathway contribute to cell division, proliferation, migration, and apoptotic cell death of human and animal. Mutation in this gene may cause the development of several cancers, including lung, skin, colon, and neuroblastoma. Currently, a few available drugs are being used that has developed by targeting the BRAF mutated protein, and due to the toxic side effects, patients suffer a lot during their treatment. Therefore this study aimed to identify potentially lead compounds that can target and block the expression of BRAF and subsequently inhibit the cancer. The hits were generated through the pharmacophore model-based virtual screening, molecular docking, pharmacohore model validation, ADME ((absorption, distribution, metabolism, and excretion) analysis molecular dynamics (MD) simulation to find more suitable candidate against the overexpress BRAF gene. The pharmacophore based screening initially identified 14k possible hits from online database which were further screened by ligand scout advance software to get hit compound. Based on molecular docking score of ZINC70454679 (-10.6kcal/mol), ZINC253500968 (-9.4kcal/mol), ZINC106887736 (-8.6kcal/mol), and ZINC107434492 (-8.1kcal/mol), pharmacophore feature and toxicity evaluation, we selected four possible lead compounds. The dynamic simulation with Schrodinger Maestro software was used to determine the stability of the potential lead candidates with target protein (PDB ID: 5VAM). The results showed that the newly obtained four compounds were more stable than the control ligand (Pub Chem ID: 90408826). The current results showed that the ZINC70454679, ZINC253500968, ZINC106887736, and ZINC107434492 compounds may be able to work against several cancers through targeting the BRAF overexpressed gene. To develop a novel drug candidate, however the evaluation of the web lab based experimental work are necessary to evaluate the efficiency of the each compound against the BRAF target gene.

9,105 views

20 citations

ORIGINAL RESEARCH
30 September 2022
Identification of compelling inhibitors of human norovirus 3CL protease to combat gastroenteritis: A structure-based virtual screening and molecular dynamics study
Shan He, 12 more and Abdul Rahaman

3,961 views

5 citations